I saw a patient in clinic last Monday. Susan is 67 years old with severe COPD. She told me she has been taking her Trelegy inhaler every other day since January- to make it last longer. Her Medicare insurance plan changed this year and with it a change in her deductible. She was paying 75$ a month for Trelegy in 2025, but since January it is $380 per month until she meets her yearly deductible. Then $175 per month. She is retired on a fixed income and simply can’t make the math work. During the visit, she wasn’t even complaining. She just wanted to make sure using the inhaler every other day would be okay.
This is the context for everything that follows. Not a policy failure in the abstract. A real person with severe lung disease, choosing between her inhaler and her grocery bill. Without daily Trelegy, her shortness of breath worsens, her cough worsens, her lungs work harder.
I’ve seen frequently since January. Patient who have already done the math before they walk through my door. Who have already decided, quietly, that breathing may have to wait.
Let’s talk about why Susan’s inhaler costs $380.
The thing that almost nobody knows
In 2008, the United States EPA banned chlorofluorocarbon propellants from metered-dose inhalers. CFCs damage the ozone layer. The ban was the right call for the environment.
But what happened next was not a coincidence.
Every CFC-based inhaler on the market — including generic albuterol, which had been available for decades and cost almost nothing had to be reformulated. New propellant. New device. New manufacturing process. And under U.S. patent law, a new formulation gets a new patent.
Generic albuterol disappeared overnight.
What replaced it were HFA-propellant versions, all under fresh new patent, all priced like new drugs. Proventil HFA. ProAir HFA. Ventolin HFA. The same molecule that had been cheap for thirty years, now in a new device, now patented, now much more expensive. Prices went from roughly $10 to $40–80 for a rescue inhaler, overnight.
The manufacturers didn’t invent a better drug. They reformulated an existing one under regulatory pressure and then patented the packaging. The patent system allowed it. No law was broken.
For maintenance inhalers — the ones patients with COPD and asthma take every day, the ones that actually keep people out of the emergency room — the same math played out over years. New combinations, new patents, new exclusivity periods. A drug that’s been on the market for two decades can get another decade of exclusivity because someone combined it with something else in a single device and filed a new patent on the result.
Then add the fact that, until very recently, Medicare was legally barred from negotiating drug prices directly. When Congress created Medicare Part D in 2003, it included something called the noninterference clause — a provision explicitly prohibiting the government from stepping in between drug manufacturers and the plan sponsors who cover your medications. The VA negotiates. The Department of Defense negotiates. Medicare could not. The Inflation Reduction Act of 2022 created a limited exception — but the first negotiated prices took effect this year, for ten drugs, none of them inhalers. The inhaler negotiations come in 2027. For the decades in between, drug companies set a list price, and that was effectively the price Medicare paid.
What actually changed — and for whom
Two things happened in the last few years that matter, and I want to be honest about both of them.
The $35 cap is real. Three major inhaler manufacturers — GSK, AstraZeneca, Boehringer Ingelheim — committed to capping out-of-pocket costs at $35 a month. For commercially insured patients and uninsured patients, this applies.
The $35 cap does not apply to Medicare. Or Medicaid. Or TRICARE. This is due to a federal law designed to prevent pharmaceutical kickbacks to physicians, written decades before manufacturer savings programs existed, now effectively bars drug companies from offering those savings to any patient covered by a federal program. The law was not written to harm elderly COPD patients. But that is what is happening.
The Inflation Reduction Act introduced a $2,000 annual out-of-pocket cap for Medicare Part D, starting 2025. This is the most meaningful thing Congress has done for Medicare drug costs in years. Before 2025, there was no cap at all. Before 2025, a patient on multiple expensive medications could spend $8,000 in a year and Medicare had no ceiling on it.
The cap is real. It is not $35. On Trelegy at standard coinsurance, you’re paying out of pocket for most of the year before it kicks in. But once you hit $2000 ($2100 in 2026) your drug is free through December 31.
Trelegy and Breo Ellipta are now subject to Medicare price negotiation under the Inflation Reduction Act. New negotiated prices take effect January 2027. I don’t know what the final cost will be. I’ve been telling patients to watch for it, which is an unsatisfying thing to say to someone who can’t afford their refill now.
Generic inhalers in 2026: the situation is complicated
Generic albuterol — rescue inhalers — is back. Around $20–30 out of pocket at GoodRx. If you’re paying significantly more than that for albuterol, something is wrong with how your prescription is configured and I recommend to check with your pharmacist. One thing to know- not every Medicare Part D plan actually covers generic albuterol — only about 69% do, despite it being a generic. Brand-name Proventil, counterintuitively, is covered by 96% of plans. It’s worth checking your specific plan’s formulary.
For maintenance inhalers, it’s more complicated.
Generic budesonide/formoterol — sold as Breyna — became available in the US in 2024. Same active ingredients as Symbicort. About $97 on GoodRx versus $334–396 for the brand.
Generic fluticasone/salmeterol, the Advair equivalent, also exists. Wixela runs $55-110.
Generic tiotropium in the HandiHaler device — a Spiriva equivalent — can be had for $80 on GoodRx. This is the most underused substitution I see clinically. Patients on brand Spiriva at $683 retail who could be on generic tiotropium at a fraction of the cost, with identical efficacy. Often the switch requires nothing more than a prescription change.
There is no generic Trelegy. No generic Breztri. No generic Anoro. No generic Spiriva Respimat — the Respimat device itself is proprietary. If your medication is in one of these categories, the options for affordability are different: manufacturer assistance programs, formulary navigation, or in some cases a clinical switch your doctor can make without restarting the prior authorization process from scratch.
One note on GoodRx: it’s legitimate and often genuinely useful. The catch is structural — paying cash through GoodRx means that cost doesn’t count toward your Medicare Part D deductible or your $2,100 out of pocket (OOP) cap. For cheap generics, GoodRx often wins even accounting for this. For expensive maintenance inhalers when you’re tracking toward the OOP cap anyway, you’re usually better off staying inside your Part D plan. Your pharmacist can run both numbers in about two minutes. Ask them.
What I tell patients
When someone sits across from me and says they’re rationing their inhaler, I don’t have a clean answer. I have a set of questions: What insurance do you have? What drug exactly? What did you pay last time? Have you ever applied for Extra Help? Does your income qualify for a manufacturer program? Have you checked GoodRx or Costplus for out of pocket cost?
Most of the time there’s something we can find to make it affordable. A generic that works as well. A program they’ve never heard of. A nebulized alternative covered under a completely different part of Medicare (Part B). A formulary tier appeal worth filing.
My patient, Susan, who was dosing every other day — we found a way to get her Trelegy more affordable. It took three phone calls and filling out two forms to get her into a manufacturer assistance program. It should not require a physician making three phone calls and two forms to solve a problem created by patent law and more than a decade old EPA environmental regulation.
That’s where we are in 2026, in the United States. We cover some real options in Part 2- options most patients and many doctors aren’t even aware of.
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.